Key points are not available for this paper at this time.
// Yin Peng 1,4,* , Xiaojing Zhang 1,3,* , Xianling Feng 1 , Xinmim Fan 1 and Zhe Jin 1,2,3 1 Department of Pathology, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People’s Republic of China 2 Shenzhen Key Laboratory of Micromolecule Innovatal Drugs, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People’s Republic of China 3 Shenzhen Key Laboratory of Translational Medicine in Tumors, The Shenzhen University School of Medicine, Shenzhen, Guangdong, People’s Republic of China 4 Department of Pathology, Wuhan University School of Basic Medical Sciences, Hubei, People’s Republic of China * These authors have contributed equally to this work Correspondence to: Zhe Jin, email: // Keywords : microRNA; Wnt/β-catenin signaling pathway; cancer Received : January 15, 2016 Accepted : October 21, 2016 Published : October 26, 2016 Abstract Mounting evidence has indicated microRNA (miR) dysregulation and the Wnt/β-catenin signaling pathway jointly drive carcinogenesis, cancer metastasis, and drug-resistance. The current review will focus on the role of the crosstalk between miRs and the Wnt/β-catenin signaling pathway in cancer development. MiRs were found to activate or inhibit the canonical Wnt pathway at various steps. On the other hand, Wnt activation increases expression of miR by directly binding to its promoter and activating transcription. Moreover, there are mutual feedback loops between some miRs and the Wnt/β-catenin signaling pathway. Clinical trials of miR-based therapeutic agents are investigated for solid and hematological tumors, however, challenges concerning low bioavailability and possible side effects must be overcome before the final clinical application. This review will describe current understanding of miR crosstalk with the Wnt/β-catenin signaling cascade. Better understanding of the regulatory network will provide insight into miR-based therapeutic development.
Peng et al. (Wed,) studied this question.